Home » Business News » 2012 » December » December 21, 2012

Bavarian Nordic Issues Revised Financial Calendar for 2013

December 21, 2012 - London

KVISTGAARD, Denmark, December 21, 2012 - Bavarian Nordic A/S (OMX: BAVA) announced today a revised financial calendar for the year 2013. The company has moved the announcement of the 2012 Annual Report from 7 March 2013 to 12 March 2013.

12 March 2013 2012 Annual Report
17 April 2013 Annual General Meeting
16 May 2013 First quarterly report (Q1) for the three-month period ended 31 March 2013
22 August 2013 Half-year report (Q2) for the six-month period ended 30 June 2013
14 November 2013 Third quarterly report (Q3) for the nine-month period ended 30 September 2013

Pursuant to Article 12 of the Articles of Association, shareholders who wish to submit a request for proposals for consideration at the Annual General Meeting must lodge this with the Company no later than Thursday, March 7, 2013.

Moreover, it should be noted that Bavarian Nordic in a period of two weeks before planned publication of quarterly reports (silent periods), will not comment specifically on developments or financial issues and expectations. The dates for silent periods will be published on the company's website:

Asger Aamund
Chairman of the Board

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE



Comment on this story